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a-Klotho, a known anti-aging protein, exerts diverse physiological effects
including: maintenance of phosphate and calcium homeostasis, modulation of
cell proliferation, and enhanced buffering of reactive oxygen species. However,
the role of a-Klotho in the regulation of energy metabolism is complex and
poorly understood. Here we investigated the effects of 5 weeks peripheral
administration of a-Klotho in high fat diet induced obese mice. Food intake,
blood glucose, and body weight were measured daily. Energy expenditure was
determined with indirect calorimetry and body composition with magnetic
resonance imaging. Liver and adipose tissue were collected for lipid content
measurements and gene expression analysis. a-Klotho-treated mice experienced
reduced adiposity, increased lean mass, and elevated energy expenditure, despite
no changes in food intake, body weight, or fed blood glucose levels. Lipid
accumulation in liver and adipose tissue was also reduced compared to controls.
Furthermore, Real-time quantitative PCR showed reduced expression of key.e01494





Article Nowe01494lipogenic genes in a-Klotho treated mice in these organs. Taken together, these data
suggest encouraging therapeutic potential of a-Klotho and highlight a need for
further research into the specific mechanisms explaining improved body
composition, elevated energy expenditure, and reduced lipid content in both liver
and adipose tissue in a-Klotho-treated mice.
Keywords: Molecular biology, Physiology
1. Introduction
Obesity is associated with dysregulated body-weight homeostasis, and is the primary
risk factor for the development of type 2 diabetes, hypertension, and cardiovascular
disease [1]. Obesity continues to reach epidemic proportions in North America,
elevating morbidity and mortality rates, while providing a cumbersome economic
burden. These trends highlight a need for further development in the field of meta-
bolic physiology, an area that has been advanced by the identification of endogenous
compounds regulating food intake and energy expenditure.
One such compound is a-Klotho, an anti-aging protein secreted by the kidney and
the brain to exhibit multiple hormonal effects [2] including: maintenance of vitamin
D and calcium homeostasis [3, 4], modulation of cell senescence [5], and production
of reactive oxygen species buffering enzymes [6]. a-Klotho may also be associated
with whole-body energy metabolism, evidenced by impaired circulating a-Klotho
concentrations in obese and diabetic human patients [7, 8]. a-Klotho overexpression
in db/db mice attenuates hyperglycemia and hyperphagia [6], and can even extend
the lifespan in healthy mice [9]. Furthermore, genetic deletion of a-Klotho sup-
presses uncoupling protein 1 gene expression, decreases temperature in brown adi-
pose tissue, and trends to increase food intake relative to body weight [10].
Despite this encouraging evidence, the specific role of a-Klotho in regulation of en-
ergy homeostasis is complicated and not completely understood. For example,
similar to overexpression models, genetic knockdown of a-Klotho in mice also in-
creases insulin sensitivity [11]. a-Klotho provides negative feedback to insulin and
IGF-1 signaling to modulate cell proliferation and improve tolerance to oxidative
stress [12, 13, 14, 15], but also facilitates insulin release via transient receptor protein
channel modification and improved calcium flux [16]. Additionally, a-Klotho dele-
tion promotes extreme leanness, but ultimately results in premature death in mouse
models [9, 17]. These mice experience drastically impaired development, manifest-
ing as osteoporosis, reduced adiposity, and atrophied organs [10, 17].
Overall, a-Klotho’s exact involvement in the pathophysiology, or even treatment, of
obesity is not understood completely.Models genetically altering a-Klotho levels pro-
vide encouraging evidence indicating a prominent role of a-Klotho in whole-bodyon.2019.e01494





Article Nowe01494energy metabolism, however, these models have conflicting results and lack insight
into a-Klotho’s tissue-specific mechanisms of action. Consequently, this study aimed
to investigate the effects of intraperitoneal a-Klotho administration on the physiology
of metabolically active organs. Furthermore, this model provides a direct translational
look into the therapeutic potential of a-Klotho to treat obesity and metabolic disease.2. Materials and methods
2.1. Materials
2.1.1. Animals
All aspects of animal care and experimentation were conducted in accordance with
the National Institutes Health “Guide for the Care and Use of Laboratory Animals”
(NIH Publication No. 85-23, revised 1996) and approved by the Institutional Animal
Care and Use Committees of East Carolina Diabetes and Obesity Institute. 24
C57BL6 male mice (JAX Stock No: 00664) from Jackson lab (The Jackson Labo-
ratory, Bar Harbor, Maine) were fed a high-fat diet with a kilocalorie composition
of 58%, 25%, and 17% fat, carbohydrate, and protein respectively for 8 weeks
(D12331, Research Diets, New Brunswick, NJ). Mice were housed under controlled
temperatures at 22e24 C and a 12 h light/12 h dark cycle.2.1.2. Reagent
The recombinant mouse a-Klotho protein (aa 35-982) was obtained from R & D
Systems (Minneapolis, MN).2.2. Methods
2.2.1. Treatment protocol
Six-week-old, male, C57BL/6 mice were fed a high-fat diet (HFD) for 8 weeks.
Mice were then intraperitoneally treated with a-Klotho protein (0.02 mg/kg) or sa-
line every 48 h. for 5 weeks. At week 18 (4 weeks into a-Klotho or saline treatment)
indirect calorimetry was performed and at week 19 mice were euthanized for further
analysis of metabolically active tissues.2.2.2. Body composition and food intake
Body weight and food intake were recorded weekly. Total fat and lean mass were
assessed using EchoMRI (Echo Medical Systems, Houston, TX). Epididymal white
adipose tissue (eWAT) was harvested. Mice were individually housed for 1 week,
followed by weekly measurement of food intake. Food intake data were combined,
averaged, and analyzed by unpaired Student’s t tests. To maximize accuracy of foodon.2019.e01494





Article Nowe01494intake measurements, a white bedding paper under the food bowl was used to collect
residual food crumbs and all uneaten food was measured. This amount was sub-
tracted from the total food given to calculate total amount of food intake.2.2.3. Energy expenditure
Energy expenditure was measured by assessing oxygen consumption with indirect
calorimetry. Individually housed male mice on a HFD and 18 weeks of age (4 weeks
into a-Klotho or saline treatment) were studied, using the Comprehensive Lab An-
imal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH). Mice
were acclimated in the CLAMS chambers for 72 hours before data collection.
Mice had free access to food and water for the duration of the studies. Values
from individual time points were totaled and analyzed by unpaired Student’s t tests
comparing two groups. All data were normalized for body weight.2.2.4. Histopathology
At the end of the experiment, livers were frozen in liquid hydrogen and then cryostat-
sectioned at a thickness of 5 mm onto poly-l-lysine slides for lipid deposition analysis
by Oil Red O staining. eWAT was frozen in liquid hydrogen and then cryostat-
sectioned at a thickness of 20 mm onto poly-l-lysine slides for adipocyte size mea-
surement. The red areas and adipocyte size were quantified by Image J [18].2.2.5. Quantitative real-time PCR
Total RNA from liver or eWAT was extracted using TRIzol reagent (Invitrogen) and
subjected to quantitative real-time PCR as described previously [19]. Gene-specific
primer sequences are listed in Supplemental Table 1. Relative gene expressions were
calculated with the delta-delta CT method with 18s ribosomal RNA normalization,
using ViiA 7 system (Applied Biosystems).2.2.6. Triglyceride content in blood, adipose tissue and liver
To quantify changes in triglyceride concentrations in blood, adipose tissue, and liver,
a Triglyceride Colorimetric Assay Kit (Cat. # 10010303, Cayman Chemical, Ann
Arbor MI) was used according to the manufacturer’s instruction. Each biological
replicate was analyzed in duplicate.2.2.7. Statistical analysis
Data are expressed as the mean  SEM. Unpaired Student’s t tests were used
throughout this study to compare two distinct groups using GraphPad Prism 5 soft-
ware (San Diego, CA). P < 0.05 was considered statistically significant.on.2019.e01494






3.1. a-Klotho improves body composition in obese mice despite
no changes in food intake and body weight
There were no differences in food intake and body weight between a-Klotho and
saline groups throughout the experiment (Fig. 1a and b). Despite no changes in
body weight, at the end of the experiment fat mass was decreased (Saline:
38.3%  1.0% versus a-Klotho: 34.0%  0.6%) (Fig. 1c) and lean mass wasFig. 1. a-Klotho decreases fat mass and increases lean mass without changing body weight or food
intake. (a) Food intake, (b) Body weight, (c) Percent fat mass, (d) Percent lean mass, (e) Fed glucose
levels, (f) Liver glycogen content, and (g) Serum triglyceride concentrations in a-Klotho treated and con-
trol mice. Bar graphs show Mean þ SEM. n ¼ 6e7 per group; * indicates p < 0.05 vs saline group.
on.2019.e01494





Article Nowe01494increased (Saline: 54.8%  1.2% versus a-Klotho: 60.0%  0.7%) (Fig. 1d) in a-
Klotho treated mice. There were no differences in fed glucose levels, liver glycogen
contents, and serum triglyceride concentrations between groups (Fig. 1e, f, g).3.2. a-Klotho increases energy expenditure in obese mice
Energy expenditure was measured via indirect calorimetry using the Comprehensive
Lab Animal Monitoring System over 7 days. Data were collected and analyzed from
the last four days (Fig. 2a). a-Klotho-treated mice show significantly increased ox-
ygen consumption during both day time (Saline: 2333  113 ml/h/kg versus a-Klo-
tho: 2628  206 ml/h/kg) (Fig. 2b) and night time (Saline: 2726  135 ml/h/kg
versus a-Klotho: 3182  263 ml/h/kg) (Fig. 2c).Fig. 2. a-Klotho increases energy expenditure. (a) Oxygen consumption normalized to body weight, (b)
Oxygen consumption during the day time, (c) and night time in a-Klotho treated and control mice. Bar
graphs show Mean þ SEM. n ¼ 6e7 per group. * indicates p < 0.05 vs saline group.
on.2019.e01494





Article Nowe014943.3. a-Klotho reduces lipid accumulation in liver and white
adipose tissue of obese mice
5-weeks administration of a-Klotho decreased lipid accumulation in the liver
(Fig. 3a and b) (Frozen sections were stained by Oil Red O) and quantified
by Image J (Fig. 3b). Triglyceride content was significantly decreased in a-Klotho
treated mice compared with controls (Saline: 48.4  3.3 mg/g versus a-Klotho:
37.7  2.2 mg/g) (Fig. 3c). a-Klotho treatment also significantly decreased adipo-
cyte size (Fig. 3d and e) and triglyceride content in epididymal white adipose tissue
(Saline: 113.2  25.2 mg/g versus a-Klotho: 75.7  11.9 mg/g) (Fig. 3f).3.4. a-Klotho modulates key gene expression related to lipid
metabolism in liver and white adipose tissue
To elucidate the molecular mechanism of a-Klotho’s lipid lowering effects, we
investigated expression of key genes related to lipid metabolism in liver and adipose
tissue. Compared to saline-treated controls, a-Klotho treated mice had changes in
liver gene expression associated with decreased lipogenesis, including reductions
in ACC-a (0.75 fold) and ACC-b (0.60 fold) (Fig. 4a). Interestingly, ACOX1
(0.48 fold), PGC1a (0.6 fold), and PPARg (0.65 fold), genes associated with fat
oxidation, were also decreased in the livers of the a-Klotho group compared to con-
trols (Fig. 4b). There were no changes in key gene expressions involved in hepatic
glucose metabolism (Fig. 4c). In white adipose tissue, a-Klotho-treated mice showed
significantly increased ACOX1 (2.2 fold) gene expression, while PPARa (0.63 fold)
and PGC1a (0.7 fold) were decreased compared with controls (Fig. 4e). We also
found strong trends toward decreased PPARg and ACC-b and strong trends toward
increased CPT1 and leptin in the adipose tissue of a-Klotho treated mice compared
with controls (Fig. 4d, e and f). In brown adipose tissue, there was no alteration in
key gene expression involved in thermogenesis (Fig. 4g).4. Discussion
The discovery of the “anti-aging protein” a-Klotho has generated research interest
that has significantly advanced our current understanding of the aging process.
Although a-Klotho was identified nearly 20 years ago, its specific function involving
energy metabolism and related disease-states remains incompletely understood. We
investigated the effects of intraperitoneal a-Klotho injection in the high fat diet
induced obese (DIO) mouse model. We revealed a previously uncovered beneficial
role of a-Klotho in the regulation of lipid accumulation in liver and adipose tissue.
Overall, a-Klotho treatment resulted in elevated energy expenditure, decreased fat
mass, and increased lean mass, despite no change in food intake or body weight.on.2019.e01494
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. a-Klotho reduces liver lipid content and decreases adipocyte size. (a) Oil red o staining of liver,
(b) Quantification of lipid area, and (c) liver triglyceride content, (d) Representative images of eWAT
sections, (e) Quantification of adipocyte size, and (f) Epididymal white adipose tissue triglyceride content
in a-Klotho treated and control mice. Bar graphs show Mean þ SEM. n ¼ 6e7 per group; The scale bars
represent 50 mm * indicates p < 0.05 vs saline group.
8 https://doi.org/10.1016/j.heliyon.2019.e01494
2405-8440/ 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 4. The effects of a-Klotho on gene expression in liver, eWAT, and BAT. (a) Hepatic levels of key
gene expression involved in lipogenesis, (b) fat oxidation, (c) glucose metabolism. (d) eWAT levels of
key gene expression involved in in lipogenesis, (e) fat oxidation, (f) secreting cytokines. (g) BAT levels
of key gene expression involved in thermogenesis in a-Klotho treated and control mice. Bar graphs show




Article Nowe01494Further gene expression analysis began to elucidate the tissue-specific mechanisms
underlying a-Klotho regulation of liver and adipose tissue metabolism.
In the livers of DIO mice treated with a-Klotho for 5 weeks, gene expression of the
two isoforms of Acetyl-CoA carboxylase (ACC) was significantly decreased, indi-
cating reduced inhibition of CPT-1, and increased fat oxidation. In the adipose tissue
of a-Klotho-treated mice, ACOX1 and CPT1 gene expression was elevated, alsoon.2019.e01494





Article Nowe01494suggesting increased fat oxidation. Interestingly, the thermogenic gene expression
(UCP1) was not altered in a-Klotho treated mice, suggesting that browning of white
adipose tissue is unlikely. a-Klotho also does not increase key gene expression asso-
ciated with thermogenesis in brown adipose tissue. Moreover, decreased PPARg
and PGC1a mRNA in both these tissues indicates reduced lipogenesis. Notably,
there were no changes in gene expressions that related to hepatic glucose meta-
bolism, such as Phosphoglycerate Kinase 1 (PGK1), Glucose 6-phosphatase
(G6Pase), Glucokinase (GK), liver type pyruvate kinase (L-PK), and Phosphoenol-
pyruvate carboxykinase (PEPCK). Supporting this data, no change in fed blood
glucose levels were observed. However, no assays were performed during the fasted
status. Due to this limitation, we cannot rule out the possibility that a-Klotho alters
glucose levels or gene expression related to glucose metabolism during fasting con-
ditions. Nonetheless, our data suggest distinct responses in lipid upon a-Klotho
administration. The general trends in a-Klotho-induced changes in liver and adipose
gene expression illustrate a shift in lipid metabolism favoring oxidation rather than
storage. This metabolic shift would explain the reduced lipid accumulation observed
in a-Klotho-treated DIO mice.
Interestingly, a-Klotho knock-out mice experience atrophy in many metabolic or-
gans, including adipose tissue and liver [9, 10]. One report even observed a-Klotho
to induce C/EBPa- and PPARg gene expression, which promotes adipocyte differ-
entiation in cultured 3T3-L1 adipocytes [20]. While the source of discrepancy be-
tween the studies is not clear, it is evident that the nature of a-Klotho’s role in
regulation of adipogenesis and lipid metabolism is complex. Additional research
is still needed and the signaling mechanisms responsible for a-Klotho-mediated
changes in lipid-related gene expression remain unknown.
Overall the current study indicates improved energy expenditure and reduced
adiposity in a-Klotho-treated DIO mice. This encouraging therapeutic potential is
supported by past literature observing beta cell specific a-Klotho overexpression
to attenuate the progression of diabetes via improved insulin release and ROS buff-
ering [6, 16, 21]. Furthermore, in a-Klotho deficient mice, non-shivering thermogen-
esis and gene expression of uncoupling protein 1 are impaired, while gluconeogenic
gene expression in the liver is elevated [10]. However, the role of a-Klotho in the
pathophysiology of metabolic disease is complex. a-Klotho overexpressing mice
live longer, but experience insulin resistance [9]. Interestingly, these mice do not
experience hyperglycemia, adiposity, or hyperphagia associated with clinical insulin
resistance [9]. Conversely, mice with impaired a-Klotho gene expression have
increased insulin sensitivity, but experience many disease phenotypes associated
with accelerated aging [10, 17]. These convoluted results may be explained by
a-Klotho acting as a homeostatic modulator of insulin and IGF-1 signaling to pre-
vent hypoglycemia, and enhance FOXO activity to reduce apoptosis and improve
ROS buffering [9, 22, 23].on.2019.e01494





Article Nowe01494Currently, the major gap in knowledge regarding a-Klotho’s functions continues to
be uncertainty surrounding the direct targets of a-Klotho. For example, the receptor
for a-Klotho has yet to be discovered. Emerging evidence suggests that a-Klotho
forms constitutive scaffolding complexes with fibroblast growth factor receptors
(FGFR’s) 1c, 3c, and 4 to increase the affinity of these FGFRs to fibroblast growth
factor (FGF23) [24]. Since FGFRs are ubiquitous, but a-Klotho expression is tissue-
specific, it seems a-Klotho’s presence governs whether a cell is an FGF23 target.
Furthermore, FGFR’s affinity to FGF23 in the absence of a-Klotho is very low, indi-
cating a-Klotho may be required to activate FGFRs and their downstream signaling
molecules [11]. It is possible that the a-Klotho-FGFR complex and subsequent
signaling pathways may be responsible for a-Klotho’s roles regulating energy meta-
bolism. This hypothesis is supported by the previously described FGF21-FGFR
signaling mechanisms that result in elevated energy expenditure, improved insulin
signaling, and reversed hepatic steatosis in DIO mice [25, 26]. Specifically, deletion
of FGFR1c in adipose tissue abolished the therapeutic ability of FGFs to lower
plasma glucose, increase insulin and triglycerides, and alter serum levels of adipo-
kines [26]. Furthermore, dominant-negative fibroblast growth factor receptor
(FGFR) expression in hepatocytes of transgenic mice resulted in a fatty liver pheno-
type [27]. Taken together these studies suggest FGFR signaling in adipose tissue and
liver is important to homeostatic regulation of fat metabolism. Future studies should
investigate the hypothesis that a-Klotho may result in activation of FGFR1 and its
downstream signaling pathway, leading to transcriptional changes related to lipid
metabolism and reduced adiposity.
Among many signaling pathways activated by FGFRs, PI3Kinase (PI3K) signaling
is involved in homeostatic regulation of energy metabolism [28, 29, 30, 31]. Acti-
vated PI3K signaling phosphorylates forkhead box proteins, FOXO1, FOXO3a,
and FOXO4, preventing translocation into the nucleus, and resulting in a loss of their
transcriptional activity [32]. One report suggests that FOXO1 positively regulates
adipogenesis through its binding to the promoter region of PPARg [33]. Therefore,
FGFR-mediated PI3kinase signaling, and subsequent FOXO1 inhibition, could be a
possible mechanism explaining reduced adiposity via decreased PPARg activity.
Although a-Klotho is theoretically not permeable to the blood brain barrier (BBB)
due to its molecular size [34], there is a recent study reporting that a-Klotho-F, a
fragment of the a-Klotho protein described in this study, can acutely improve cogni-
tive and motor functions following peripheral administration in young, aging, and
hSYN transgenic mice [35]. One must consider that some of the lipid reducing ef-
fects by a-Klotho may also be associated with the central nervous system (CNS).
However, how peripheral a-Klotho transmits a signal to the CNS remains to be
answered. Possibilities include modification of other circulating factors that can
cross the BBB or alteration of central a-Klotho levels, either directly or indirectly.on.2019.e01494





Article Nowe01494Our study does not rule out that a-Klotho might also act with the CNS but, rather,
poses the question of the possibility of such a phenomenon.
In conclusion, our study demonstrates that 5-weeks administration of a-Klotho im-
proves adiposity in DIO mice, mainly via lowering the lipid accumulation in liver
and adipose tissue. The observed shift in lipid metabolism favoring oxidation rather
than storage in liver and adipose begins to shed light on the tissue specific mecha-
nisms responsible for a-Klotho’s role in energy metabolism. The encouraging ther-
apeutic potential of a-Klotho shown in the current study highlights a need for further
research into this phenomenon, including investigations into likely a-Klotho
induced FGFR1 signaling in liver and adipose tissue.Declarations
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